Lilly’s Trulicity exceedes Sanofi’s Lantus in efficacy for type 2 diabetics

Data reported at 75th American Diabetes Association Scientific Sessions strengthen existing facts on Trulicity’s safety and efficacy.

Eli Lilly’s (LLY +0.2%) Trulicity (dulaglutide) injection offered superior hemoglobin A1c  reduction compared to Sanofi’s (NYSE: SNY) Lantus (insulin glargine [RDNA origin] injection) in a study of patients with type 2 diabetes, according to new data presented.

After 26 weeks, both doses of Trulicity were more efficient in  A1c reduction, and more patients reached the recommended A1c target of less than 7 percent. The decrease in A1c from baseline for Trulicity 0.75 mg, Trulicity 1.5 mg and Lantus were -1.32%, -1.7% and -1.15%, respectively.

Patients receiving 0.75 mg and 1.5 mg Trulicity lost an average of 0.88 kg and 1.51 kg weight, correspondingly, whereas those receiving Lantus gained an average of 0.96 kg.

In the study, Trulicity was well-endured, showing fewer reports of hypoglycemia in patients treated with Trulicity compared to Lantus. Other side-effects were gastrointestinal in nature, with more Trulicity-treated patients experiencing diarrhea (15.2 percent [Trulicity 1.5 mg], 8.4 percent [Trulicity 0.75 mg]) and nausea (8.7 percent [Trulicity 1.5 mg], 4.9 percent [Trulicity 0.75 mg]) compared to Lantus (1.6 percent [diarrhea] and 0.8 percent [nausea]). These outcomes were consistent with previous Trulicity studies.

Trulicity was approved by the U.S. Food and Drug Administration (FDA) in September 2014 and European Commission granted marketing authorization two months later.




Leave a Reply

Your email address will not be published. Required fields are marked *